Ro 48-8071 (free base)

• Description:

  Ro 48-8071 is an inhibitor of OSC (Oxidosqualene cyclase) with IC50 of appr 6.5 nM.

• UNSPSC:

  12352005

• Hazard Statement:

  H302-H315-H319-H335

• Target:

  Apoptosis; Estrogen Receptor/ERR

• Type:

  Reference compound

• Related Pathways:

  Apoptosis; Vitamin D Related/Nuclear Receptor

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/Ro-48-8071.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C (C1=CC=C (Br) C=C1) C2=CC=C (OCCCCCCN (C) CC=C) C=C2F

• Molecular Formula:

  C23H27BrFNO2

• Molecular Weight:

  448.37

• Precautions:

  P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

• References & Citations:

  [1]Morand OH, et al. Ro 48-8.071, a new 2,3-oxidosqualene:lanosterol cyclase inhibitor lowering plasma cholesterol in hamsters, squirrel monkeys, and minipigs: comparison to simvastatin. J Lipid Res. 1997 Feb;38 (2) :373-90.|[2]Liang Y, et al. Cholesterol biosynthesis inhibitor RO 48-8071 suppresses growth of hormone-dependent and castration-resistant prostate cancer cells. Onco Targets Ther. 2016 May 30;9:3223-32|[3]Liang Y, et al. Cholesterol biosynthesis inhibitors as potent novel anti-cancer agents: suppression of hormone-dependent breast cancer by the oxidosqualene cyclase inhibitor RO 48-8071. Breast Cancer Res Treat. 2014 Jul;146 (1) :51-62.|[4]Chuang JC, et al. Sustained and selective suppression of intestinal cholesterol synthesis by Ro 48-8071, an inhibitor of 2,3-oxidosqualene:lanosterol cyclase, in the BALB/c mouse. Biochem Pharmacol. 2014 Apr 1;88 (3) :351-63.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Citation 01:

  ACS Synth Biol. 2023 May 19;12 (5) :1408-1414.|Cancer Cell. 2023 Jul 10;41 (7) :1276-1293.e11.|Mol Cell. 2021 Jul 1;81 (13) :2736-2751.e8.|Nat Commun. 2023 Jul 17;14 (1) :4267.|Oncotarget. 2017 Feb 28;8 (9) :14860-14875.|Sci China Life Sci. 2022 Feb;65 (2) :341-361.|Cancer Res Commun. 2024 Sep 1;4 (9) :2427-2443.|Cell Death Dis. 2021 May 13;12 (5) :482.|Cell Death Discov. 2025 Feb 8;11 (1) :55.|Cell Rep. 2022 Dec 13;41 (11) :111827.|Immunomedicine. 2022 Dec;2 (2) :e1041.|Mol Med Rep. 2021 Dec;24 (6) :828.|Neoplasia. 2025 Oct 27:70:101243.

• CAS Number:

  161582-11-2